Core Strategies of Engineered Bacteriophages and Research Progress in Their Application for Disease Treatment

Xuelin LI; Zehua HAN; Xiaoyan YANG; Runzhe HE; Wenteng HOU; Ai YANG; Yuliang CHEN; Yingying XIANG

Article Contents

Article Navigation > Journal of Kunming Medical University > 2026 > Accepted Manuscript

Xuelin LI, Zehua HAN, Xiaoyan YANG, Runzhe HE, Wenteng HOU, Ai YANG, Yuliang CHEN, Yingying XIANG. Core Strategies of Engineered Bacteriophages and Research Progress in Their Application for Disease Treatment[J]. Journal of Kunming Medical University.

Citation:

PDF( 2373 KB)

Core Strategies of Engineered Bacteriophages and Research Progress in Their Application for Disease Treatment

1.
Kunming Medical University Haiyuan College
2.
Department of Stomatology
3.
Department of Dermatology，Yan'an Hospital Affiliated to Kunming Medical University，Kunming Yunnan 650031，China

Received Date: 2026-06-09

Abstract

Abstract

Bacteriophages are natural viruses that specifically lyse bacteria and possess unique advantages in antimicrobial therapy. However, natural bacteriophages have limitations including narrow host range, poor stability, and high immunogenicity. Recent advances in synthetic biology and gene editing technologies have provided powerful tools for the targeted engineering of bacteriophages. Engineering strategies such as genetic editing, chemical modification, and material encapsulation can effectively broaden the host range, enhance environmental stability, and reduce immune clearance, thereby significantly improving therapeutic efficacy. This review summarizes the core strategies for engineering bacteriophages and their research progress in anti-infection therapy, cancer treatment, and vaccine development, aiming to promote further research and clinical translation of engineered bacteriophages and to provide new solutions for addressing antibiotic resistance and expanding precision medicine applications.
- Engineered bacteriophages,
- Genome editing,
- Chemical modification,
- Material encapsulation

FullText(HTML)

References(60)

References

[1]	Netea M G, Schlitzer A, Placek K, et al. Innate and adaptive immune memory: An evolutionary continuum in the host’s response to pathogens[J]. Cell Host Microbe, 2019, 25(1): 13-26. doi: 10.1016/j.chom.2018.12.006
[2]	Sahoo K, Meshram S. The evolution of phage therapy: A comprehensive review of current applications and future innovations[J]. Cureus, 2024, 16(9): e70414. doi: 10.7759/cureus.70414
[3]	Venkataraman S, Shahgolzari M, Yavari A, et al. Bacteriophages as targeted therapeutic vehicles: Challenges and opportunities[J]. Bioengineering (Basel), 2025, 12(5): 469. doi: 10.3390/bioengineering12050469
[4]	Hussain W, Yang X, Ullah M, et al. Genetic engineering of bacteriophages: Key concepts, strategies, and applications[J]. Biotechnol Adv, 2023, 64: 108116. doi: 10.1016/j.biotechadv.2023.108116
[5]	Cao X, Yu T, Sun Z, et al. Engineered phages in anti-infection and anti-tumor fields: A review[J]. Microb Pathogen, 2025, 198: 107052. doi: 10.1016/j.micpath.2024.107052
[6]	Ding B, Fan M, Shi Y P, et al. Mechanistic roles and therapeutic potential of bacteriophages in inflammatory gastrointestinal diseases[J]. Microbiome Res Rep, 2025, 4(4): 40. doi: 10.20517/mrr.2025.62
[7]	Xiang Y, Yang R, Li X, et al. Phage PEf771 for the treatment of periapical periodontitis induced by Enterococcus faecalis YN771[J]. Crit Rev Immunol, 2024, 44(1): 41-53. doi: 10.1615/CritRevImmunol.2023050313
[8]	韩泽华, 杨小燕, 陈昱良, 等. 噬菌体在龋病防治中的研究进展[J]. 昆明医科大学学报, 2026, 47(1): 140-147. doi: 10.12259/j.issn.2095-610X.S20260117
[9]	Zhang S, Kim J C, Ahn J. Phage engineering strategies to expand host range for controlling antibiotic-resistant pathogens[J]. Microbiol Res, 2025, 300: 128278. doi: 10.1016/j.micres.2025.128278
[10]	Xiang Y, Ma C, Yin S, et al. Phage therapy for refractory periapical periodontitis caused by Enterococcus faecalis in vitro and in vivo[J]. Appl Microbiol Biotechnol, 2022, 106(5-6): 2121-2131. doi: 10.1007/s00253-022-11810-8
[11]	Xiang Y, Wang S, Huang H, et al. A novel endolysin from an Enterococcus faecalis phage and application[J]. Microb Pathogen, 2024, 192: 106689. doi: 10.1016/j.micpath.2024.106689
[12]	Kim P, Sanchez A M, Penke T J R, et al. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): The randomised, open-label, first part of a two-part phase 2 trial[J]. Lancet Infect Dis, 2024, 24(12): 1319-1332. doi: 10.1016/S1473-3099(24)00424-9
[13]	Yue Y, Xu Z, Soteyome T, et al. Phage encapsulation and delivery technology: A strategy for treating drug-resistant pathogenic microorganisms[J]. Pharmaceuticals (Basel), 2025, 18(11): 1688. doi: 10.3390/ph18111688
[14]	Yang Y, Li R, Zhong Q, et al. In situ gut microbiota editing: Enhancing therapeutic efficacy for bacterial colitis by compatible oral hydrogel microspheres with phages[J]. Nat Commun, 2025, 16(1): 9785. doi: 10.1038/s41467-025-65498-1
[15]	Ramadan MA, Ali MA, El-Badawy MF, et al. Phage display technology: a promising platform for cancer targeting, drug delivery, and vaccine development[J]. Future J Pharm Sci, 2025, 11: 74. doi: 10.1186/s43094-025-00825-3
[16]	Chongchai A, Bentayebi K, Chu G, et al. Targeted treatment of chondrosarcoma with a bacteriophage-based particle delivering a secreted tumor necrosis factor-related apoptosis-inducing ligand[J]. Mol Ther Oncol, 2024, 32(2): 200805. doi: 10.1016/j.omton.2024.200805
[17]	Kim S Y, Kim Y J, Kim M S. Protective efficacy of miR-155 encapsulated using MS2 bacteriophage-based virus-like particle (MS2-VLP) against viral hemorrhagic septicemia virus (VHSV) in olive flounder[J]. Fish Shellfish Immunol, 2026, 168: 111000. doi: 10.1016/j.fsi.2025.111000
[18]	Lenneman B R, Fernbach J, Loessner M J, et al. Enhancing phage therapy through synthetic biology and genome engineering[J]. Curr Opin Biotechnol, 2021, 68: 151-159. doi: 10.1016/j.copbio.2020.11.003
[19]	Mahler M, Costa A R, van Beljouw S P B, et al. Approaches for bacteriophage genome engineering[J]. Trends Biotechnol, 2023, 41(5): 669-685. doi: 10.1016/j.tibtech.2022.08.008
[20]	Morrical S W. The bacteriophage T4 homologous recombination system: Mechanism, applications, conservation, and environmental significance[J]. EcoSal Plus, 2025, 13(1): eesp00032025. doi: 10.1128/ecosalplus.esp-0003-2025
[21]	Alessa O, Aiba Y, Arbaah M, et al. Synthetic and functional engineering of bacteriophages: Approaches for tailored bactericidal, diagnostic, and delivery platforms[J]. Molecules, 2025, 30(15): 3132. doi: 10.3390/molecules30153132
[22]	Payaslian F, Gradaschi V, Piuri M. Genetic manipulation of phages for therapy using BRED[J]. Curr Opin Biotechnol, 2021, 68: 8-14. doi: 10.1016/j.copbio.2020.09.005
[23]	Wetzel K S, Guerrero-Bustamante C A, Dedrick R M, et al. CRISPY-BRED and CRISPY-BRIP: Efficient bacteriophage engineering[J]. Sci Rep, 2021, 11: 6796. doi: 10.1038/s41598-021-86112-6
[24]	Costa A R, Azeredo J, Pires D P. Synthetic biology to engineer bacteriophage genomes[M]//Bacteriophage Therapy. New York, NY: Springer, 2023: 261-277.
[25]	Deng W, Li Y, Shao Y, et al. Engineering yeast chromosomal telomeres with a bacteriophage system[J]. Nat Commun, 2026, 17(1): 6571. doi: 10.1038/s41467-026-73335-2
[26]	Chaudhary N, Sharma K, Kaur H, et al. CRISPR-Cas-assisted phage engineering for personalized antibacterial treatments[J]. Indian J Med Microbiol, 2025, 53: 100771. doi: 10.1016/j.ijmmb.2024.100771
[27]	Marinelli L J, Piuri M, Hatfull G F. Genetic manipulation of lytic bacteriophages with BRED: Bacteriophage recombineering of electroporated DNA[J]. Methods Mol Biol, 2019, 1898: 69-80.
[28]	Kakkar A, Kandwal G, Nayak T, et al. Engineered bacteriophages: A Panacea against pathogenic and drug resistant bacteria[J]. Heliyon, 2024, 10(14): e34333. doi: 10.1016/j.heliyon.2024.e34333
[29]	Ando H, Lemire S, Pires D P, et al. Engineering modular viral scaffolds for targeted bacterial population editing[J]. Cell Syst, 2015, 1(3): 187-196. doi: 10.1016/j.cels.2015.08.013
[30]	Doudna J A, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9[J]. Science, 2014, 346(6213): 1258096. doi: 10.1126/science.1258096
[31]	Camara-Wilpert S, Mayo-Muñoz D, Russel J, et al. Bacteriophages suppress CRISPR-Cas immunity using RNA-based anti-CRISPRs[J]. Nature, 2023, 623(7987): 601-607. doi: 10.1038/s41586-023-06612-5
[32]	Khambhati K, Bhattacharjee G, Gohil N, et al. Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens[J]. Bioeng Transl Med, 2023, 8(2): e10381. doi: 10.1002/btm2.10381
[33]	Huss P, Raman S. Engineered bacteriophages as programmable biocontrol agents[J]. Curr Opin Biotechnol, 2020, 61: 116-121. doi: 10.1016/j.copbio.2019.11.013
[34]	Souza E B, Pinto A R, Fongaro G. Bacteriophages as potential clinical immune modulators[J]. Microorganisms, 2023, 11(9): 2222. doi: 10.3390/microorganisms11092222
[35]	Guan J, Oromí-Bosch A, Mendoza S D, et al. Bacteriophage genome engineering with CRISPR-Cas13a[J]. Nat Microbiol, 2022, 7(12): 1956-1966. doi: 10.1038/s41564-022-01243-4
[36]	Hameed M, Hu Y, Khan A, et al. Chemically mediated modification of bacteriophages: Strategies, functionalities and applications in precision medicine[J]. Nanomed Nanotechnol Biol Med, 2026, 74: 102944. doi: 10.1016/j.nano.2026.102944
[37]	Peng H, Borg R E, Dow L P, et al. Controlled phage therapy by photothermal ablation of specific bacterial species using gold nanorods targeted by chimeric phages[J]. Proc Natl Acad Sci U S A, 2020, 117(4): 1951-1961. doi: 10.1073/pnas.1913234117
[38]	Peng H, Chen I A. Preparation of bioconjugates of chimeric M13 phage and gold nanorods[M]//Phage Engineering and Analysis: Methods and Protocols. New York, NY: Springer US, 2024: 131-141.
[39]	Brown L, Vidal A V, Dias A L, et al. Proximity-driven site-specific cyclization of phage-displayed peptides[J]. Nat Commun, 2024, 15: 7308. doi: 10.1038/s41467-024-51610-4
[40]	Jin L, Cao F, Gao Y, et al. Microenvironment-activated nanozyme-armed bacteriophages efficiently combat bacterial infection[J]. Adv Mater, 2023, 35(30): e2301349. doi: 10.1002/adma.202301349
[41]	Ma Y, Pacan J C, Wang Q, et al. Microencapsulation of bacteriophage felix O1 into chitosan-alginate microspheres for oral delivery[J]. Appl Environ Microbiol, 2008, 74(15): 4799-4805. doi: 10.1128/AEM.00246-08
[42]	Hsu B B, Plant I N, Lyon L, et al. In situ reprogramming of gut bacteria by oral delivery[J]. Nat Commun, 2020, 11(1): 5030. doi: 10.1038/s41467-020-18614-2
[43]	Singla S, Harjai K, Raza K, et al. Phospholipid vesicles encapsulated bacteriophage: A novel approach to enhance phage biodistribution[J]. J Virol Methods, 2016, 236: 68-76. doi: 10.1016/j.jviromet.2016.07.002
[44]	Colom J, Cano-Sarabia M, Otero J, et al. Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp[J]. Appl Environ Microbiol, 2015, 81(14): 4841-4849. doi: 10.1128/AEM.00812-15
[45]	Meng L, Yang F, Pang Y, et al. Nanocapping-enabled charge reversal generates cell-enterable endosomal-escapable bacteriophages for intracellular pathogen inhibition[J]. Sci Adv, 2022, 8(28): eabq2005. doi: 10.1126/sciadv.abq2005
[46]	Dedrick R M, Guerrero-Bustamante C A, Garlena R A, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus[J]. Nat Med, 2019, 25(5): 730-733. doi: 10.1038/s41591-019-0437-z
[47]	Weiner I, Kahan-Hanum M, Buchstab N, et al. Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: A randomized first-in-human trial[J]. Nat Commun, 2025, 16(1): 5579. doi: 10.1038/s41467-025-60598-4
[48]	Bayat F, Stark M, Rahmani S, et al. AI-assisted phage formulation delivered via injectable hydrogels for localized control of implant-associated infections[J]. Bioact Mater, 2026, 63: 578-595.
[49]	Walter N, Brochhuasen C, EL Khassawna T, et al. Hydrogel-based local delivery of bacteriophages for infection control: A systematic review of in vivo evidence[J]. Journal of Controlled Release, 2026, 399: 115335. doi: 10.1016/j.jconrel.2026.115335
[50]	Kaltenbrunner A, Martino A, Nigro M, et al. Conjugating M13 bacteriophage targeting folate receptor alpha with multiple photosensitizers: A flexible phototheranostic platform against ovarian cancer[J]. J Mater Chem B, 2026, 14(23): 7164-7178. doi: 10.1039/D5TB02844B
[51]	Mangeat T, Mairaville C, Chentouf M, et al. Generation using phage-display of pH-dependent antibodies against the tumor-associated antigen AXL[J]. Antibodies (Basel), 2025, 14(4): 83. doi: 10.3390/antib14040083
[52]	Mustafa B S, Nagalo B M, Tesfay M, et al. Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer[J]. Cancer Res, 2025, 85(8_Supplement_1): 2155.
[53]	Bush M, Rajaure M, Gentilucci C, et al. Lambda phage-based antibody-stimulating platform targeting EGFRvIII[J]. Vaccines, 2026, 14(3): 282. doi: 10.3390/vaccines14030282
[54]	Zhu J, Sha J, Batra H, et al. A modular bacteriophage T4 nanoparticle platform enables rapid design of dual COVID-19-flu mucosal vaccines[J]. Small Sci, 2025, 5(4): 2400580. doi: 10.1002/smsc.202400580
[55]	Wroe J A, Johnson C T, García A J. Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo[J]. J Biomed Mater Res A, 2020, 108(1): 39-49. doi: 10.1002/jbm.a.36790
[56]	Ghafouri E, Fadaie M, Amirkhani Z, et al. Evaluation of humoral and cellular immune responses against Vibrio cholerae using oral immunization by multi-epitope-phage-based vaccine[J]. Int Immunopharmacol, 2024, 134: 112160. doi: 10.1016/j.intimp.2024.112160
[57]	Alessa O, Aiba Y, Arbaah M, et al. Synthetic and functional engineering of bacteriophages: Approaches for tailored bactericidal, diagnostic, and delivery platforms[J]. Molecules, 2025, 30(15): 3132. doi: 10.3390/molecules30153132
[58]	International Organization for Standardization. Biotechnology—Bioprocessing—General requirements for bacteriophage preparation for therapeutic use: ISO/TS 20853: 2026[S]. Geneva: ISO, 2026.
[59]	Zhu J, Tao P, Chopra A K, et al. Bacteriophage T4 as a protein-based, adjuvant- and needle-free, mucosal pandemic vaccine design platform[J]. Annu Rev Virol, 2024, 11(1): 395-420. doi: 10.1146/annurev-virology-111821-111145
[60]	Kumar A, Krishan B, Dhiman S, et al. Beyond antibiotics: Innovative and translational strategies to overcome antimicrobial resistance[J]. 3 Biotech, 2026, 16(6): 201. doi: 10.1007/s13205-026-04836-6

Relative Articles(20)

Relative Articles

[1]	Zehua HAN, Xiaoyan YANG, Yuliang CHEN, Xuelin LI, Rongyu YANG, Yingying XIANG. Research Progress on Bacteriophage Prevention and Treatment of Dental Caries. Journal of Kunming Medical University,
[2]	Zehua HAN, Xiaoyan YANG, Lian LI, Yuliang CHEN, Ai YANG, Xuelin LI, Yingying XIANG. Application and Mechanism of Endolysins in Bacteriophages. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20260601
[3]	Zehua HAN, Xiaoyan YANG, Yuliang CHEN, Xuelin LI, Rongyu YANG, Yingying XIANG. Research Progress on Bacteriophage Prevention and Treatment of Dental Caries. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20260117
[4]	Xiang LI, Zhaoyang CHU, Hengli YANG, Changzeng FENG, Li LI, Jiansheng LIU, Shaohui MA. Genomic Analysis of Two Novel Coxsackievirus B2 Strains in 2022. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20260502
[5]	Wanying XIE, Jingjing XIONG, Zhanhua LI, Qingyao YANG, Yongkun HUANG, Meng LI. Metagenomic Analysis of Gut Microbiome in Infants with or without Breast Milk Jaundice. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20260806
[6]	Yahong SUN, Xiaoyu YANG, Rui ZHENG. Progress and Challenges in the Study of Bacteriophage Therapy for Carbapenem-Resistant Klebsiella Pneumoniae Infection. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250621
[7]	Xuelin LI, Xiaoyan YANG, Zehua HAN, Yuliang CHEN, Xingyuan XU, Chunyan ZHANG, Yingying XIANG. Synergistic Mechanisms and Applications of Phage-antibiotic Combination Therapy. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20251201
[8]	Hao HUANG, Xuelin LI, Zehua HAN, Lin CHANG, Pengfei ZHU, Yingying XIANG. Application of Bacteriophages in Common Infectious Diseases of the Oral Cavity. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250122
[9]	Dan MA, Yajuan ZHANG, Binbin MA, Qiaoning YUE, Jianping LIU. Genomic Analysis of Cellular Senescence and Osteoporosis Target Genes and Small Molecule Screening. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250220
[10]	Jinli ZHAO, Hongyan YANG, Jiaqian YANG, Xinyi CHEN, Qing ZHAO, Xiaomei ZHANG. Studies on the Chemical Epigenetic Modification of Fungus Samsoniella Hepiali CDB9-31. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250802
[11]	Zhaoyang CHU, Jialing LI, Junwei CHEN, Changzeng FENG, Ming ZHANG, Li LI, Shaohui MA. Whole Genome Analysis of Coxsackievirus A10 in Yunnan Province. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250204
[12]	Rongyu YANG, Fei SONG, Yunlin WEI, Xianghong YANG, Kaiwen Duan, Yingying XIANG. Effects of Different Accumulation Culture Methods on the Titer of Phage PEf771. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220218
[13]	Junhong MAO, Danfeng LU, Yu XU, Yicong DAI, Zherui ZHANG, Yue LI, Kunhua WANG. Methamphetamine Alters Methylation Modifications of Synaptic Plasticity Genes in Addicted Mice. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220121
[14]	Yi-sheng QIAO, Xiao-xiang CHEN, Jiao-tian XU, Wei WANG, Chao ZHANG, Xiao-bin SONG, Zhi-yong YANG, Xing-li DENG. Transplantation of Nurr1 Gene-modified Embryo Midbrain Neural Stem Cells for Treatment of Parkinson’s Rats. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210919
[15]	Yi-sheng QIAO, Xiao-xiang CHEN, Jiao-tian XU, Wei WANG, Chao ZHANG, Xiao-bin SONG, Zhi-yong YANG, Xing-li DENG. Transplantation of Nurr1 Gene-modified Embryo Midbrain Neural Stem Cells for Treatment in Parkinson’ s Disease. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210801
[16]	Xiang Ying Ying , Song Fei , Yang Xiang Hong , Zhou Jing , Yu Hong Bin , Wei Yun Lin , Ji Xiu Ling . . Journal of Kunming Medical University,
[17]	Dai Run , Zhang Chan , Cheng Yu Jing , Chen Wan Lu , Li Qi , Wang Yu Ming . . Journal of Kunming Medical University,
[18]	Yang Jin Rong , Ruan Jing Yan , Zeng Yun , Wu Kun , Nie Bo , Wang Xue Jiao . . Journal of Kunming Medical University,
[19]	Li Xiao Fei . . Journal of Kunming Medical University,
[20]	Wu Gao Li . . Journal of Kunming Medical University,